Novartis's Sandoz May Appeal to US Supreme Court in Biosimilar Erelzi Case
July 01 2020 - 1:00PM
Dow Jones News
By Pietro Lombardi
Novartis AG's Sandoz division is evaluating its options,
including a potential appeal to the U.S. Supreme Court, after a
U.S. court ruled against the company in a patent litigation related
to the Sandoz biosimilar Erelzi.
The Swiss drugmaker said Wednesday that the U.S. Court of
Appeals for the Federal District upheld a previous ruling declaring
Amgen Inc.'s patents valid.
"Sandoz will continue its efforts to make Erelzi available to
U.S. patients with autoimmune and inflammatory diseases," said
Carol Lynch, president of Sandoz U.S. and head of North America.
"Our company respects valid intellectual property, however Sandoz
continues to believe the patents asserted by Amgen are not valid,
and that it should not be able to use them to extend the drug's
exclusivity."
Sandoz's biosimilar Erelzi was approved by the U.S. Food and
Drug Administration in 2016 but the company hasn't been able to
launch it in the U.S. due to the patent litigation with Amgen.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
July 01, 2020 12:45 ET (16:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024